Global Immunology and Inflamatory Diseases Drugs Market - 2025 -2033
Immunology & Inflammatory Diseases Drugs Market Size
The global immunology & inflammatory diseases drugs market size reached US$ 212.76 Billion in 2024 from US$ 197.84 Billion in 2023 and is expected to reach US$ 431.11 Billion by 2033, growing at a CAGR of 8.2% during the forecast period 2025-2033.
Overview
The global immunology & inflammatory diseases drugs market is experiencing robust growth, driven by a confluence of factors including an aging population, rising prevalence of autoimmune and inflammatory disorders, and significant advancements in biologic therapies. Key therapeutic areas such as rheumatoid arthritis, psoriasis, inflammatory bowel diseases, and multiple sclerosis are witnessing increased treatment demand. Monoclonal antibodies, Janus kinase (JAK) inhibitors, and interleukin inhibitors are leading the innovation front, with drugs like AbbVie’s Rinvoq and Skyrizi, setting new standards in efficacy and patient outcomes. The growing adoption of biologics, including biosimilars, is expected to drive market expansion further, offering more cost-effective treatment options and improving patient access globally.
Dynamics
Drivers:
The rising prevalence of autoimmune and inflammatory diseases is significantly driving the immunology & inflammatory diseases drugs market growth
According to the National Institutes of Health, in the United States alone, over 15 million individuals, approximately 4.6% of the population, have been diagnosed with at least one autoimmune disease and 34% of those are diagnosed with more than 1 autoimmune disease, with many affected by multiple conditions simultaneously. This increase in prevalence is contributing to a higher demand for effective treatments.
Recent advancements in drug development have led to the introduction of several innovative therapies targeting these diseases. For instance, in June 2025, Johnson & Johnson announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking to expand approval of STELARA (ustekinumab) for the treatment of children two years and older with moderately to severely active Crohn’s disease (CD). STELARA is currently approved for the treatment of adults living with moderately to severely active CD and ulcerative colitis, in addition to the treatment of adults and children six years and older with active psoriatic arthritis and moderate to severe plaque psoriasis.
These developments underscore the significant impact of the increasing prevalence of autoimmune and inflammatory diseases on the growth of the immunology & inflammatory diseases drugs market. The demand for effective treatments is driving innovation and the introduction of new therapies, thereby expanding the market and offering hope to patients affected by these chronic conditions.
Restraints:
Safety concerns and side effects are hampering the growth of the immunology & inflammatory diseases drugs market
Safety concerns and side effects associated with immunology and inflammatory disease drugs significantly hamper market growth by limiting treatment options, increasing healthcare costs, and affecting patient compliance. Immunosuppressive drugs, such as corticosteroids and biologics, are commonly used to manage autoimmune conditions. However, their long-term use can lead to serious side effects. For instance, corticosteroids may cause weight gain, mood swings, and elevated blood pressure, while biologics can suppress the immune system, increasing susceptibility to infections and potentially leading to reactivation of latent diseases.
The side effects of these treatments can result in poor patient adherence, as individuals may discontinue therapy due to adverse reactions. This non-compliance can lead to disease flares, increased hospitalizations, and a higher overall healthcare burden. Furthermore, the development of new immunology drugs faces challenges in balancing efficacy with safety. While targeted therapies offer promising results, they must undergo rigorous testing to ensure they do not introduce new safety concerns. The need for extensive clinical trials to assess long-term safety profiles can delay the availability of new treatments and increase development costs.
Segmentation Analysis
The global immunology & inflammatory diseases drugs market is segmented based on drug class, disease indication, distribution channel, and region.
The rheumatoid arthritis (RA) segment from the disease indication is dominating the immunology & inflammatory diseases drugs market with a 35.57% share in 2024
The rheumatoid arthritis (RA) segment continues to dominate the immunology and inflammatory diseases drugs market due to its high prevalence, chronic burden, and the wide adoption of advanced therapies. Humira (adalimumab) has historically been the market leader with its global sales US$ 8,993 million in 2024. AbbVie has successfully countered the market with its newer immunology blockbusters Skyrizi (risankizumab) and Rinvoq (upadacitinib), which together generated USD 17,689 million in 2024, cementing their position as future leaders. The continuous pipeline expansion, recent product approvals like biosimilars to the available biologics, and the sustained global burden of RA, particularly in aging populations, are ensuring that the RA segment remains the largest and most influential within the immunology and inflammatory diseases drugs market.
For instance, in May 2025,Celltrion Inc. announced that the U.S. Food and Drug Administration (FDA) granted an expanded interchangeable designation for YUFLYMA (adalimumab-aaty), now including prefilled syringe (40mg) and autoinjectors (40mg and 80mg) presentations. With this approval, YUFLYMA is now fully interchangeable with the reference product, Humira (adalimumab), across all marketed dosage forms and strengths. YUFLYMA is a high-concentration, citrate-free biosimilar to Humira, approved for multiple inflammatory indications, including rheumatoid arthritis (RA).
Geographical Share Analysis
North America is expected to dominate the global immunology & inflammatory diseases drugs market with a 44.78% in 2024
North America remains the dominant region in the global immunology & inflammatory diseases drugs market, largely due to its strong healthcare ecosystem, higher prevalence of autoimmune and inflammatory conditions, rapid adoption of biologics and targeted therapies, and consistent flow of FDA approvals that keep the region at the forefront of innovation.
The region’s dominance was reinforced by multiple landmark approvals and strong product uptake. For instance, in August 2024, the FDA approved Nemluvio (nemolizumab) as the first-in-class monoclonal antibody for prurigo nodularis and atopic dermatitis, expanding therapeutic options in dermatologic immunology, in April 2025, Johnson & Johnson’s Imaavy won FDA clearance for generalized myasthenia gravis (gMG), and Amgen’s Uplizna (inebilizumab) secured approval in April 2025 for IgG4-related disease (IgG4-RD).
Meanwhile, North America continues to drive blockbuster revenues through established leaders such as AbbVie’s Humira, Skyrizi and Rinvoq, reflecting the market’s swift embrace of next-generation therapies. Together, these approvals and sales performances illustrate that North America remains the powerhouse of the immunology and inflammatory drugs market. Its combination of cutting-edge research, regulatory efficiency, high treatment uptake, and strong spending power continues to ensure that the region not only leads in revenues but also in shaping the global trajectory of immunology innovation.
Competitive Landscape
Top companies in the immunology & inflammatory diseases drugs market include AbbVie Inc., Sanofi, Regeneron Pharmaceuticals, Inc., Johnson & Johnson, Amgen Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc., Merck & Co., Inc., Bristol-Myers Squibb Company, and Eli Lilly and Company, among others.
The global immunology & inflammatory diseases drugs market report delivers a detailed analysis with 62 key tables, more than 59 visually impactful figures, and 167 pages of expert insights, providing a complete view of the market landscape.
The global immunology & inflammatory diseases drugs market size reached US$ 212.76 Billion in 2024 from US$ 197.84 Billion in 2023 and is expected to reach US$ 431.11 Billion by 2033, growing at a CAGR of 8.2% during the forecast period 2025-2033.
Overview
The global immunology & inflammatory diseases drugs market is experiencing robust growth, driven by a confluence of factors including an aging population, rising prevalence of autoimmune and inflammatory disorders, and significant advancements in biologic therapies. Key therapeutic areas such as rheumatoid arthritis, psoriasis, inflammatory bowel diseases, and multiple sclerosis are witnessing increased treatment demand. Monoclonal antibodies, Janus kinase (JAK) inhibitors, and interleukin inhibitors are leading the innovation front, with drugs like AbbVie’s Rinvoq and Skyrizi, setting new standards in efficacy and patient outcomes. The growing adoption of biologics, including biosimilars, is expected to drive market expansion further, offering more cost-effective treatment options and improving patient access globally.
Dynamics
Drivers:
The rising prevalence of autoimmune and inflammatory diseases is significantly driving the immunology & inflammatory diseases drugs market growth
According to the National Institutes of Health, in the United States alone, over 15 million individuals, approximately 4.6% of the population, have been diagnosed with at least one autoimmune disease and 34% of those are diagnosed with more than 1 autoimmune disease, with many affected by multiple conditions simultaneously. This increase in prevalence is contributing to a higher demand for effective treatments.
Recent advancements in drug development have led to the introduction of several innovative therapies targeting these diseases. For instance, in June 2025, Johnson & Johnson announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking to expand approval of STELARA (ustekinumab) for the treatment of children two years and older with moderately to severely active Crohn’s disease (CD). STELARA is currently approved for the treatment of adults living with moderately to severely active CD and ulcerative colitis, in addition to the treatment of adults and children six years and older with active psoriatic arthritis and moderate to severe plaque psoriasis.
These developments underscore the significant impact of the increasing prevalence of autoimmune and inflammatory diseases on the growth of the immunology & inflammatory diseases drugs market. The demand for effective treatments is driving innovation and the introduction of new therapies, thereby expanding the market and offering hope to patients affected by these chronic conditions.
Restraints:
Safety concerns and side effects are hampering the growth of the immunology & inflammatory diseases drugs market
Safety concerns and side effects associated with immunology and inflammatory disease drugs significantly hamper market growth by limiting treatment options, increasing healthcare costs, and affecting patient compliance. Immunosuppressive drugs, such as corticosteroids and biologics, are commonly used to manage autoimmune conditions. However, their long-term use can lead to serious side effects. For instance, corticosteroids may cause weight gain, mood swings, and elevated blood pressure, while biologics can suppress the immune system, increasing susceptibility to infections and potentially leading to reactivation of latent diseases.
The side effects of these treatments can result in poor patient adherence, as individuals may discontinue therapy due to adverse reactions. This non-compliance can lead to disease flares, increased hospitalizations, and a higher overall healthcare burden. Furthermore, the development of new immunology drugs faces challenges in balancing efficacy with safety. While targeted therapies offer promising results, they must undergo rigorous testing to ensure they do not introduce new safety concerns. The need for extensive clinical trials to assess long-term safety profiles can delay the availability of new treatments and increase development costs.
Segmentation Analysis
The global immunology & inflammatory diseases drugs market is segmented based on drug class, disease indication, distribution channel, and region.
The rheumatoid arthritis (RA) segment from the disease indication is dominating the immunology & inflammatory diseases drugs market with a 35.57% share in 2024
The rheumatoid arthritis (RA) segment continues to dominate the immunology and inflammatory diseases drugs market due to its high prevalence, chronic burden, and the wide adoption of advanced therapies. Humira (adalimumab) has historically been the market leader with its global sales US$ 8,993 million in 2024. AbbVie has successfully countered the market with its newer immunology blockbusters Skyrizi (risankizumab) and Rinvoq (upadacitinib), which together generated USD 17,689 million in 2024, cementing their position as future leaders. The continuous pipeline expansion, recent product approvals like biosimilars to the available biologics, and the sustained global burden of RA, particularly in aging populations, are ensuring that the RA segment remains the largest and most influential within the immunology and inflammatory diseases drugs market.
For instance, in May 2025,Celltrion Inc. announced that the U.S. Food and Drug Administration (FDA) granted an expanded interchangeable designation for YUFLYMA (adalimumab-aaty), now including prefilled syringe (40mg) and autoinjectors (40mg and 80mg) presentations. With this approval, YUFLYMA is now fully interchangeable with the reference product, Humira (adalimumab), across all marketed dosage forms and strengths. YUFLYMA is a high-concentration, citrate-free biosimilar to Humira, approved for multiple inflammatory indications, including rheumatoid arthritis (RA).
Geographical Share Analysis
North America is expected to dominate the global immunology & inflammatory diseases drugs market with a 44.78% in 2024
North America remains the dominant region in the global immunology & inflammatory diseases drugs market, largely due to its strong healthcare ecosystem, higher prevalence of autoimmune and inflammatory conditions, rapid adoption of biologics and targeted therapies, and consistent flow of FDA approvals that keep the region at the forefront of innovation.
The region’s dominance was reinforced by multiple landmark approvals and strong product uptake. For instance, in August 2024, the FDA approved Nemluvio (nemolizumab) as the first-in-class monoclonal antibody for prurigo nodularis and atopic dermatitis, expanding therapeutic options in dermatologic immunology, in April 2025, Johnson & Johnson’s Imaavy won FDA clearance for generalized myasthenia gravis (gMG), and Amgen’s Uplizna (inebilizumab) secured approval in April 2025 for IgG4-related disease (IgG4-RD).
Meanwhile, North America continues to drive blockbuster revenues through established leaders such as AbbVie’s Humira, Skyrizi and Rinvoq, reflecting the market’s swift embrace of next-generation therapies. Together, these approvals and sales performances illustrate that North America remains the powerhouse of the immunology and inflammatory drugs market. Its combination of cutting-edge research, regulatory efficiency, high treatment uptake, and strong spending power continues to ensure that the region not only leads in revenues but also in shaping the global trajectory of immunology innovation.
Competitive Landscape
Top companies in the immunology & inflammatory diseases drugs market include AbbVie Inc., Sanofi, Regeneron Pharmaceuticals, Inc., Johnson & Johnson, Amgen Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc., Merck & Co., Inc., Bristol-Myers Squibb Company, and Eli Lilly and Company, among others.
The global immunology & inflammatory diseases drugs market report delivers a detailed analysis with 62 key tables, more than 59 visually impactful figures, and 167 pages of expert insights, providing a complete view of the market landscape.
1. MARKET INTRODUCTION AND SCOPE
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Drug Class
2.4. Snippet by Disease Indication
2.5. Snippet by Distribution Channel
2.6. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Rising Prevalence of Autoimmune and Inflammatory Diseases
3.1.1.2. Expanding Applications of Existing Drugs
3.1.2. Restraints
3.1.2.1. Safety Concerns and Side Effects
3.1.2.2. High Treatment Costs and Accessibility
3.1.3. Opportunity
3.1.3.1. Advancements in Personalized Medicine
3.1.3.2. Emergence of Biosimilars
3.1.4. Impact Analysis
4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established Leaders with the Largest Marketing Brand
4.1.3. Market Leaders with Established Products
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. South America
4.3.5. Middle East & Africa
4.4. Porter’s Five Forces Analysis
4.5. Patent Analysis
4.6. Unmet Needs and Gaps
4.7. Recommended Strategies for Market Entry and Expansion
4.8. Pricing Analysis and Price Dynamics
5. IMMUNOLOGY & INFLAMMATORY DISEASES DRUGS MARKET, BY DRUG CLASS
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
5.1.2. Market Attractiveness Index, By Drug Class
5.2. Monoclonal Antibodies (mAbs)*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Immunosuppressants
5.4. Antibody-Drug Conjugates
5.5. Immune Checkpoint Inhibitors
5.6. Polyclonal Antibodies
5.7. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
5.8. Others
6. IMMUNOLOGY & INFLAMMATORY DISEASES DRUGS MARKET, BY DISEASE INDICATION
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
6.1.2. Market Attractiveness Index, By Disease Indication
6.2. Rheumatoid Arthritis (RA)*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Psoriatic Arthritis
6.4. Plaque Psoriasis
6.5. Inflammatory Bowel Disease (IBD)
6.6. Ankylosing Spondylitis
6.7. Others
7. IMMUNOLOGY & INFLAMMATORY DISEASES DRUGS MARKET, BY DISTRIBUTION CHANNEL
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
7.1.2. Market Attractiveness Index, By Distribution Channel
7.2. Hospital Pharmacies*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Retail Pharmacies
7.4. Online Pharmacies
8. IMMUNOLOGY & INFLAMMATORY DISEASES DRUGS MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
8.1.2. Market Attractiveness Index, By Region
8.2. North America
8.2.1. Introduction
8.2.2. Key Region-Specific Dynamics
8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.2.6.1. U.S.
8.2.6.2. Canada
8.2.6.3. Mexico
8.3. Europe
8.3.1. Introduction
8.3.2. Key Region-Specific Dynamics
8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.3.6.1. Germany
8.3.6.2. UK
8.3.6.3. France
8.3.6.4. Spain
8.3.6.5. Italy
8.3.6.6. Rest of Europe
8.4. Asia-Pacific
8.4.1. Introduction
8.4.2. Key Region-Specific Dynamics
8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.4.6.1. China
8.4.6.2. India
8.4.6.3. Japan
8.4.6.4. South Korea
8.4.6.5. Rest of Asia-Pacific
8.4.7. South America
8.4.7.1. Introduction
8.4.7.2. Key Region-Specific Dynamics
8.4.7.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
8.4.7.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
8.4.7.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
8.4.7.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.4.7.6.1. Brazil
8.4.7.6.2. Argentina
8.4.7.6.3. Rest of South America
8.5. Middle East and Africa
8.5.1. Introduction
8.5.2. Key Region-Specific Dynamics
8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
9.1. Competitive Overview and Key Market Players
9.2. Market Share Analysis and Positioning Matrix
9.3. Strategic Partnerships, Mergers & Acquisitions
9.4. Key Developments in Product Portfolios and Innovations
9.5. Company Benchmarking
10. COMPANY PROFILES
10.1. AbbVie Inc.*
10.1.1. Company Overview
10.1.2. Product Portfolio
10.1.2.1. Product Description
10.1.2.2. Product Key Performance Indicators (KPIs)
10.1.3. Financial Overview
10.1.3.1. Company Revenue
10.1.3.2. Geographical Revenue Shares
10.1.3.3. Revenue Forecasts
10.1.4. Key Developments
10.1.4.1. Mergers & Acquisitions
10.1.4.2. Key Product Development Activities
10.1.4.3. Regulatory Approvals, etc.
10.1.4.4. SWOT Analysis
10.2. Sanofi
10.3. Regeneron Pharmaceuticals, Inc.
10.4. Johnson & Johnson
10.5. Amgen Inc.
10.6. Novartis Pharmaceuticals Corporation
10.7. Pfizer Inc.
10.8. Merck & Co., Inc.
10.9. Bristol-Myers Squibb Company
10.10. Eli Lilly and Company(LIST NOT EXHAUSTIVE)
11. ASSUMPTIONS AND RESEARCH METHODOLOGY
11.1. Data Collection Methods
11.2. Data Triangulation
11.3. Forecasting Techniques
11.4. Data Verification and Validation
12. APPENDIX
12.1. About Us and Services
12.2. Contact Us
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Drug Class
2.4. Snippet by Disease Indication
2.5. Snippet by Distribution Channel
2.6. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Rising Prevalence of Autoimmune and Inflammatory Diseases
3.1.1.2. Expanding Applications of Existing Drugs
3.1.2. Restraints
3.1.2.1. Safety Concerns and Side Effects
3.1.2.2. High Treatment Costs and Accessibility
3.1.3. Opportunity
3.1.3.1. Advancements in Personalized Medicine
3.1.3.2. Emergence of Biosimilars
3.1.4. Impact Analysis
4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established Leaders with the Largest Marketing Brand
4.1.3. Market Leaders with Established Products
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. South America
4.3.5. Middle East & Africa
4.4. Porter’s Five Forces Analysis
4.5. Patent Analysis
4.6. Unmet Needs and Gaps
4.7. Recommended Strategies for Market Entry and Expansion
4.8. Pricing Analysis and Price Dynamics
5. IMMUNOLOGY & INFLAMMATORY DISEASES DRUGS MARKET, BY DRUG CLASS
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
5.1.2. Market Attractiveness Index, By Drug Class
5.2. Monoclonal Antibodies (mAbs)*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Immunosuppressants
5.4. Antibody-Drug Conjugates
5.5. Immune Checkpoint Inhibitors
5.6. Polyclonal Antibodies
5.7. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
5.8. Others
6. IMMUNOLOGY & INFLAMMATORY DISEASES DRUGS MARKET, BY DISEASE INDICATION
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
6.1.2. Market Attractiveness Index, By Disease Indication
6.2. Rheumatoid Arthritis (RA)*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Psoriatic Arthritis
6.4. Plaque Psoriasis
6.5. Inflammatory Bowel Disease (IBD)
6.6. Ankylosing Spondylitis
6.7. Others
7. IMMUNOLOGY & INFLAMMATORY DISEASES DRUGS MARKET, BY DISTRIBUTION CHANNEL
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
7.1.2. Market Attractiveness Index, By Distribution Channel
7.2. Hospital Pharmacies*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Retail Pharmacies
7.4. Online Pharmacies
8. IMMUNOLOGY & INFLAMMATORY DISEASES DRUGS MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
8.1.2. Market Attractiveness Index, By Region
8.2. North America
8.2.1. Introduction
8.2.2. Key Region-Specific Dynamics
8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.2.6.1. U.S.
8.2.6.2. Canada
8.2.6.3. Mexico
8.3. Europe
8.3.1. Introduction
8.3.2. Key Region-Specific Dynamics
8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.3.6.1. Germany
8.3.6.2. UK
8.3.6.3. France
8.3.6.4. Spain
8.3.6.5. Italy
8.3.6.6. Rest of Europe
8.4. Asia-Pacific
8.4.1. Introduction
8.4.2. Key Region-Specific Dynamics
8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.4.6.1. China
8.4.6.2. India
8.4.6.3. Japan
8.4.6.4. South Korea
8.4.6.5. Rest of Asia-Pacific
8.4.7. South America
8.4.7.1. Introduction
8.4.7.2. Key Region-Specific Dynamics
8.4.7.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
8.4.7.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
8.4.7.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
8.4.7.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.4.7.6.1. Brazil
8.4.7.6.2. Argentina
8.4.7.6.3. Rest of South America
8.5. Middle East and Africa
8.5.1. Introduction
8.5.2. Key Region-Specific Dynamics
8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
9.1. Competitive Overview and Key Market Players
9.2. Market Share Analysis and Positioning Matrix
9.3. Strategic Partnerships, Mergers & Acquisitions
9.4. Key Developments in Product Portfolios and Innovations
9.5. Company Benchmarking
10. COMPANY PROFILES
10.1. AbbVie Inc.*
10.1.1. Company Overview
10.1.2. Product Portfolio
10.1.2.1. Product Description
10.1.2.2. Product Key Performance Indicators (KPIs)
10.1.3. Financial Overview
10.1.3.1. Company Revenue
10.1.3.2. Geographical Revenue Shares
10.1.3.3. Revenue Forecasts
10.1.4. Key Developments
10.1.4.1. Mergers & Acquisitions
10.1.4.2. Key Product Development Activities
10.1.4.3. Regulatory Approvals, etc.
10.1.4.4. SWOT Analysis
10.2. Sanofi
10.3. Regeneron Pharmaceuticals, Inc.
10.4. Johnson & Johnson
10.5. Amgen Inc.
10.6. Novartis Pharmaceuticals Corporation
10.7. Pfizer Inc.
10.8. Merck & Co., Inc.
10.9. Bristol-Myers Squibb Company
10.10. Eli Lilly and Company(LIST NOT EXHAUSTIVE)
11. ASSUMPTIONS AND RESEARCH METHODOLOGY
11.1. Data Collection Methods
11.2. Data Triangulation
11.3. Forecasting Techniques
11.4. Data Verification and Validation
12. APPENDIX
12.1. About Us and Services
12.2. Contact Us
LIST OF TABLES
Table 1 Global Immunology & Inflammatory Diseases Drugs Market Value, By Drug Class, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global Immunology & Inflammatory Diseases Drugs Market Value, By Disease Indication, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global Immunology & Inflammatory Diseases Drugs Market Value, By Distribution Channel, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global Immunology & Inflammatory Diseases Drugs Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global Immunology & Inflammatory Diseases Drugs Market Value, By Drug Class, 2025, 2029 & 2033 (US$ Billion)
Table 6 Global Immunology & Inflammatory Diseases Drugs Market Value, By Drug Class, 2022-2033 (US$ Billion)
Table 7 Global Immunology & Inflammatory Diseases Drugs Market Value, By Disease Indication, 2025, 2029 & 2033 (US$ Billion)
Table 8 Global Immunology & Inflammatory Diseases Drugs Market Value, By Disease Indication, 2022-2033 (US$ Billion)
Table 9 Global Immunology & Inflammatory Diseases Drugs Market Value, By Distribution Channel, 2025, 2029 & 2033 (US$ Billion)
Table 10 Global Immunology & Inflammatory Diseases Drugs Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 11 Global Immunology & Inflammatory Diseases Drugs Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 12 Global Immunology & Inflammatory Diseases Drugs Market Value, By Region, 2022-2033 (US$ Billion)
Table 13 North America Immunology & Inflammatory Diseases Drugs Market Value, By Drug Class, 2022-2033 (US$ Billion)
Table 14 North America Immunology & Inflammatory Diseases Drugs Market Value, By Disease Indication, 2022-2033 (US$ Billion)
Table 15 North America Immunology & Inflammatory Diseases Drugs Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 16 North America Immunology & Inflammatory Diseases Drugs Market Value, By Country, 2022-2033 (US$ Billion)
Table 17 Europe Immunology & Inflammatory Diseases Drugs Market Value, By Drug Class, 2022-2033 (US$ Billion)
Table 18 Europe Immunology & Inflammatory Diseases Drugs Market Value, By Disease Indication, 2022-2033 (US$ Billion)
Table 19 Europe Immunology & Inflammatory Diseases Drugs Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 20 Europe Immunology & Inflammatory Diseases Drugs Market Value, By Country, 2022-2033 (US$ Billion)
Table 21 Asia-Pacific Immunology & Inflammatory Diseases Drugs Market Value, By Drug Class, 2022-2033 (US$ Billion)
Table 22 Asia-Pacific Immunology & Inflammatory Diseases Drugs Market Value, By Disease Indication, 2022-2033 (US$ Billion)
Table 23 Asia-Pacific Immunology & Inflammatory Diseases Drugs Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 24 Asia-Pacific Immunology & Inflammatory Diseases Drugs Market Value, By Country, 2022-2033 (US$ Billion)
Table 25 South America Immunology & Inflammatory Diseases Drugs Market Value, By Drug Class, 2022-2033 (US$ Billion)
Table 26 South America Immunology & Inflammatory Diseases Drugs Market Value, By Disease Indication, 2022-2033 (US$ Billion)
Table 27 South America Immunology & Inflammatory Diseases Drugs Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 28 South America Immunology & Inflammatory Diseases Drugs Market Value, By Country, 2022-2033 (US$ Billion)
Table 29 Middle East and Africa Immunology & Inflammatory Diseases Drugs Market Value, By Drug Class, 2022-2033 (US$ Billion)
Table 30 Middle East and Africa Immunology & Inflammatory Diseases Drugs Market Value, By Disease Indication, 2022-2033 (US$ Billion)
Table 31 Middle East and Africa Immunology & Inflammatory Diseases Drugs Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 32 Middle East and Africa Immunology & Inflammatory Diseases Drugs Market Value, By Country, 2022-2033 (US$ Billion)
Table 33 AbbVie Inc.: Overview
Table 34 AbbVie Inc.: Product Portfolio
Table 35 AbbVie Inc.: Key Developments
Table 36 Sanofi: Overview
Table 37 Sanofi: Product Portfolio
Table 38 Sanofi: Key Developments
Table 39 Regeneron Pharmaceuticals, Inc.: Overview
Table 40 Regeneron Pharmaceuticals, Inc.: Product Portfolio
Table 41 Regeneron Pharmaceuticals, Inc.: Key Developments
Table 42 Johnson & Johnson: Overview
Table 43 Johnson & Johnson: Product Portfolio
Table 44 Johnson & Johnson: Key Developments
Table 45 Amgen Inc.: Overview
Table 46 Amgen Inc.: Product Portfolio
Table 47 Amgen Inc.: Key Developments
Table 48 Novartis Pharmaceuticals Corporation: Overview
Table 49 Novartis Pharmaceuticals Corporation: Product Portfolio
Table 50 Novartis Pharmaceuticals Corporation: Key Developments
Table 51 Pfizer Inc.: Overview
Table 52 Pfizer Inc.: Product Portfolio
Table 53 Pfizer Inc.: Key Developments
Table 54 Merck & Co., Inc.: Overview
Table 55 Merck & Co., Inc.: Product Portfolio
Table 56 Merck & Co., Inc.: Key Developments
Table 57 Bristol-Myers Squibb Company: Overview
Table 58 Bristol-Myers Squibb Company: Product Portfolio
Table 59 Bristol-Myers Squibb Company: Key Developments
Table 60 Eli Lilly and Company: Overview
Table 61 Eli Lilly and Company: Product Portfolio
Table 62 Eli Lilly and Company: Key Developments
Table 1 Global Immunology & Inflammatory Diseases Drugs Market Value, By Drug Class, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global Immunology & Inflammatory Diseases Drugs Market Value, By Disease Indication, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global Immunology & Inflammatory Diseases Drugs Market Value, By Distribution Channel, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global Immunology & Inflammatory Diseases Drugs Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global Immunology & Inflammatory Diseases Drugs Market Value, By Drug Class, 2025, 2029 & 2033 (US$ Billion)
Table 6 Global Immunology & Inflammatory Diseases Drugs Market Value, By Drug Class, 2022-2033 (US$ Billion)
Table 7 Global Immunology & Inflammatory Diseases Drugs Market Value, By Disease Indication, 2025, 2029 & 2033 (US$ Billion)
Table 8 Global Immunology & Inflammatory Diseases Drugs Market Value, By Disease Indication, 2022-2033 (US$ Billion)
Table 9 Global Immunology & Inflammatory Diseases Drugs Market Value, By Distribution Channel, 2025, 2029 & 2033 (US$ Billion)
Table 10 Global Immunology & Inflammatory Diseases Drugs Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 11 Global Immunology & Inflammatory Diseases Drugs Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 12 Global Immunology & Inflammatory Diseases Drugs Market Value, By Region, 2022-2033 (US$ Billion)
Table 13 North America Immunology & Inflammatory Diseases Drugs Market Value, By Drug Class, 2022-2033 (US$ Billion)
Table 14 North America Immunology & Inflammatory Diseases Drugs Market Value, By Disease Indication, 2022-2033 (US$ Billion)
Table 15 North America Immunology & Inflammatory Diseases Drugs Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 16 North America Immunology & Inflammatory Diseases Drugs Market Value, By Country, 2022-2033 (US$ Billion)
Table 17 Europe Immunology & Inflammatory Diseases Drugs Market Value, By Drug Class, 2022-2033 (US$ Billion)
Table 18 Europe Immunology & Inflammatory Diseases Drugs Market Value, By Disease Indication, 2022-2033 (US$ Billion)
Table 19 Europe Immunology & Inflammatory Diseases Drugs Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 20 Europe Immunology & Inflammatory Diseases Drugs Market Value, By Country, 2022-2033 (US$ Billion)
Table 21 Asia-Pacific Immunology & Inflammatory Diseases Drugs Market Value, By Drug Class, 2022-2033 (US$ Billion)
Table 22 Asia-Pacific Immunology & Inflammatory Diseases Drugs Market Value, By Disease Indication, 2022-2033 (US$ Billion)
Table 23 Asia-Pacific Immunology & Inflammatory Diseases Drugs Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 24 Asia-Pacific Immunology & Inflammatory Diseases Drugs Market Value, By Country, 2022-2033 (US$ Billion)
Table 25 South America Immunology & Inflammatory Diseases Drugs Market Value, By Drug Class, 2022-2033 (US$ Billion)
Table 26 South America Immunology & Inflammatory Diseases Drugs Market Value, By Disease Indication, 2022-2033 (US$ Billion)
Table 27 South America Immunology & Inflammatory Diseases Drugs Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 28 South America Immunology & Inflammatory Diseases Drugs Market Value, By Country, 2022-2033 (US$ Billion)
Table 29 Middle East and Africa Immunology & Inflammatory Diseases Drugs Market Value, By Drug Class, 2022-2033 (US$ Billion)
Table 30 Middle East and Africa Immunology & Inflammatory Diseases Drugs Market Value, By Disease Indication, 2022-2033 (US$ Billion)
Table 31 Middle East and Africa Immunology & Inflammatory Diseases Drugs Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 32 Middle East and Africa Immunology & Inflammatory Diseases Drugs Market Value, By Country, 2022-2033 (US$ Billion)
Table 33 AbbVie Inc.: Overview
Table 34 AbbVie Inc.: Product Portfolio
Table 35 AbbVie Inc.: Key Developments
Table 36 Sanofi: Overview
Table 37 Sanofi: Product Portfolio
Table 38 Sanofi: Key Developments
Table 39 Regeneron Pharmaceuticals, Inc.: Overview
Table 40 Regeneron Pharmaceuticals, Inc.: Product Portfolio
Table 41 Regeneron Pharmaceuticals, Inc.: Key Developments
Table 42 Johnson & Johnson: Overview
Table 43 Johnson & Johnson: Product Portfolio
Table 44 Johnson & Johnson: Key Developments
Table 45 Amgen Inc.: Overview
Table 46 Amgen Inc.: Product Portfolio
Table 47 Amgen Inc.: Key Developments
Table 48 Novartis Pharmaceuticals Corporation: Overview
Table 49 Novartis Pharmaceuticals Corporation: Product Portfolio
Table 50 Novartis Pharmaceuticals Corporation: Key Developments
Table 51 Pfizer Inc.: Overview
Table 52 Pfizer Inc.: Product Portfolio
Table 53 Pfizer Inc.: Key Developments
Table 54 Merck & Co., Inc.: Overview
Table 55 Merck & Co., Inc.: Product Portfolio
Table 56 Merck & Co., Inc.: Key Developments
Table 57 Bristol-Myers Squibb Company: Overview
Table 58 Bristol-Myers Squibb Company: Product Portfolio
Table 59 Bristol-Myers Squibb Company: Key Developments
Table 60 Eli Lilly and Company: Overview
Table 61 Eli Lilly and Company: Product Portfolio
Table 62 Eli Lilly and Company: Key Developments
LIST OF FIGURES
Figure 1 Global Immunology & Inflammatory Diseases Drugs Market Value, 2022-2033 (US$ Billion)
Figure 2 Global Immunology & Inflammatory Diseases Drugs Market Share, By Drug Class, 2024 & 2033 (%)
Figure 3 Global Immunology & Inflammatory Diseases Drugs Market Share, By Disease Indication, 2024 & 2033 (%)
Figure 4 Global Immunology & Inflammatory Diseases Drugs Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 5 Global Immunology & Inflammatory Diseases Drugs Market Share, By Region, 2024 & 2033 (%)
Figure 6 Global Immunology & Inflammatory Diseases Drugs Market Y-o-Y Growth, By Drug Class, 2023-2033 (%)
Figure 7 Monoclonal Antibodies (mAbs) Immunology & Inflammatory Diseases Drugs Market Value, 2022-2033 (US$ Billion)
Figure 8 Immunosuppressants Immunology & Inflammatory Diseases Drugs Market Value, 2022-2033 (US$ Billion)
Figure 9 Antibody-Drug Conjugates Immunology & Inflammatory Diseases Drugs Market Value, 2022-2033 (US$ Billion)
Figure 10 Immune Checkpoint Inhibitors Immunology & Inflammatory Diseases Drugs Market Value, 2022-2033 (US$ Billion)
Figure 11 Polyclonal Antibodies Immunology & Inflammatory Diseases Drugs Market Value, 2022-2033 (US$ Billion)
Figure 12 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Immunology & Inflammatory Diseases Drugs Market Value, 2022-2033 (US$ Billion)
Figure 13 Others Immunology & Inflammatory Diseases Drugs Market Value, 2022-2033 (US$ Billion)
Figure 14 Global Immunology & Inflammatory Diseases Drugs Market Y-o-Y Growth, By Disease Indication, 2023-2033 (%)
Figure 15 Rheumatoid Arthritis (RA) Disease Indication in Global Immunology & Inflammatory Diseases Drugs Market Value, 2022-2033 (US$ Billion)
Figure 16 Psoriatic Arthritis Disease Indication in Global Immunology & Inflammatory Diseases Drugs Market Value, 2022-2033 (US$ Billion)
Figure 17 Plaque Psoriasis Disease Indication in Global Immunology & Inflammatory Diseases Drugs Market Value, 2022-2033 (US$ Billion)
Figure 18 Inflammatory Bowel Disease (IBD) Disease Indication in Global Immunology & Inflammatory Diseases Drugs Market Value, 2022-2033 (US$ Billion)
Figure 19 Ankylosing Spondylitis Disease Indication in Global Immunology & Inflammatory Diseases Drugs Market Value, 2022-2033 (US$ Billion)
Figure 20 Others Disease Indication in Global Immunology & Inflammatory Diseases Drugs Market Value, 2022-2033 (US$ Billion)
Figure 21 Global Immunology & Inflammatory Diseases Drugs Market Y-o-Y Growth, By Distribution Channel, 2023-2033 (%)
Figure 22 Hospital Pharmacies Distribution Channel in Global Immunology & Inflammatory Diseases Drugs Market Value, 2022-2033 (US$ Billion)
Figure 23 Retail Pharmacies Distribution Channel in Global Immunology & Inflammatory Diseases Drugs Market Value, 2022-2033 (US$ Billion)
Figure 24 Online Pharmacies Distribution Channel in Global Immunology & Inflammatory Diseases Drugs Market Value, 2022-2033 (US$ Billion)
Figure 25 Global Immunology & Inflammatory Diseases Drugs Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 26 North America Immunology & Inflammatory Diseases Drugs Market Value, 2022-2033 (US$ Billion)
Figure 27 North America Immunology & Inflammatory Diseases Drugs Market Share, By Drug Class, 2024 & 2033 (%)
Figure 28 North America Immunology & Inflammatory Diseases Drugs Market Share, By Disease Indication, 2024 & 2033 (%)
Figure 29 North America Immunology & Inflammatory Diseases Drugs Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 30 North America Immunology & Inflammatory Diseases Drugs Market Share, By Country, 2024 & 2033 (%)
Figure 31 Europe Immunology & Inflammatory Diseases Drugs Market Value, 2022-2033 (US$ Billion)
Figure 32 Europe Immunology & Inflammatory Diseases Drugs Market Share, By Drug Class, 2024 & 2033 (%)
Figure 33 Europe Immunology & Inflammatory Diseases Drugs Market Share, By Disease Indication, 2024 & 2033 (%)
Figure 34 Europe Immunology & Inflammatory Diseases Drugs Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 35 Europe Immunology & Inflammatory Diseases Drugs Market Share, By Country, 2024 & 2033 (%)
Figure 36 Asia-Pacific Immunology & Inflammatory Diseases Drugs Market Value, 2022-2033 (US$ Billion)
Figure 37 Asia-Pacific Immunology & Inflammatory Diseases Drugs Market Share, By Drug Class, 2024 & 2033 (%)
Figure 38 Asia-Pacific Immunology & Inflammatory Diseases Drugs Market Share, By Disease Indication, 2024 & 2033 (%)
Figure 39 Asia-Pacific Immunology & Inflammatory Diseases Drugs Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 40 Asia-Pacific Immunology & Inflammatory Diseases Drugs Market Share, By Country, 2024 & 2033 (%)
Figure 41 South America Immunology & Inflammatory Diseases Drugs Market Value, 2022-2033 (US$ Billion)
Figure 42 South America Immunology & Inflammatory Diseases Drugs Market Share, By Drug Class, 2024 & 2033 (%)
Figure 43 South America Immunology & Inflammatory Diseases Drugs Market Share, By Disease Indication, 2024 & 2033 (%)
Figure 44 South America Immunology & Inflammatory Diseases Drugs Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 45 South America Immunology & Inflammatory Diseases Drugs Market Share, By Country, 2024 & 2033 (%)
Figure 46 Middle East and Africa Immunology & Inflammatory Diseases Drugs Market Value, 2022-2033 (US$ Billion)
Figure 47 Middle East and Africa Immunology & Inflammatory Diseases Drugs Market Share, By Drug Class, 2024 & 2033 (%)
Figure 48 Middle East and Africa Immunology & Inflammatory Diseases Drugs Market Share, By Disease Indication, 2024 & 2033 (%)
Figure 49 Middle East and Africa Immunology & Inflammatory Diseases Drugs Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 50 AbbVie Inc.: Financials
Figure 51 Sanofi: Financials
Figure 52 Regeneron Pharmaceuticals, Inc.: Financials
Figure 53 Johnson & Johnson: Financials
Figure 54 Amgen Inc.: Financials
Figure 55 Novartis Pharmaceuticals Corporation: Financials
Figure 56 Pfizer Inc.: Financials
Figure 57 Merck & Co., Inc.: Financials
Figure 58 Bristol-Myers Squibb Company: Financials
Figure 59 Eli Lilly and Company: Financials
Figure 1 Global Immunology & Inflammatory Diseases Drugs Market Value, 2022-2033 (US$ Billion)
Figure 2 Global Immunology & Inflammatory Diseases Drugs Market Share, By Drug Class, 2024 & 2033 (%)
Figure 3 Global Immunology & Inflammatory Diseases Drugs Market Share, By Disease Indication, 2024 & 2033 (%)
Figure 4 Global Immunology & Inflammatory Diseases Drugs Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 5 Global Immunology & Inflammatory Diseases Drugs Market Share, By Region, 2024 & 2033 (%)
Figure 6 Global Immunology & Inflammatory Diseases Drugs Market Y-o-Y Growth, By Drug Class, 2023-2033 (%)
Figure 7 Monoclonal Antibodies (mAbs) Immunology & Inflammatory Diseases Drugs Market Value, 2022-2033 (US$ Billion)
Figure 8 Immunosuppressants Immunology & Inflammatory Diseases Drugs Market Value, 2022-2033 (US$ Billion)
Figure 9 Antibody-Drug Conjugates Immunology & Inflammatory Diseases Drugs Market Value, 2022-2033 (US$ Billion)
Figure 10 Immune Checkpoint Inhibitors Immunology & Inflammatory Diseases Drugs Market Value, 2022-2033 (US$ Billion)
Figure 11 Polyclonal Antibodies Immunology & Inflammatory Diseases Drugs Market Value, 2022-2033 (US$ Billion)
Figure 12 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Immunology & Inflammatory Diseases Drugs Market Value, 2022-2033 (US$ Billion)
Figure 13 Others Immunology & Inflammatory Diseases Drugs Market Value, 2022-2033 (US$ Billion)
Figure 14 Global Immunology & Inflammatory Diseases Drugs Market Y-o-Y Growth, By Disease Indication, 2023-2033 (%)
Figure 15 Rheumatoid Arthritis (RA) Disease Indication in Global Immunology & Inflammatory Diseases Drugs Market Value, 2022-2033 (US$ Billion)
Figure 16 Psoriatic Arthritis Disease Indication in Global Immunology & Inflammatory Diseases Drugs Market Value, 2022-2033 (US$ Billion)
Figure 17 Plaque Psoriasis Disease Indication in Global Immunology & Inflammatory Diseases Drugs Market Value, 2022-2033 (US$ Billion)
Figure 18 Inflammatory Bowel Disease (IBD) Disease Indication in Global Immunology & Inflammatory Diseases Drugs Market Value, 2022-2033 (US$ Billion)
Figure 19 Ankylosing Spondylitis Disease Indication in Global Immunology & Inflammatory Diseases Drugs Market Value, 2022-2033 (US$ Billion)
Figure 20 Others Disease Indication in Global Immunology & Inflammatory Diseases Drugs Market Value, 2022-2033 (US$ Billion)
Figure 21 Global Immunology & Inflammatory Diseases Drugs Market Y-o-Y Growth, By Distribution Channel, 2023-2033 (%)
Figure 22 Hospital Pharmacies Distribution Channel in Global Immunology & Inflammatory Diseases Drugs Market Value, 2022-2033 (US$ Billion)
Figure 23 Retail Pharmacies Distribution Channel in Global Immunology & Inflammatory Diseases Drugs Market Value, 2022-2033 (US$ Billion)
Figure 24 Online Pharmacies Distribution Channel in Global Immunology & Inflammatory Diseases Drugs Market Value, 2022-2033 (US$ Billion)
Figure 25 Global Immunology & Inflammatory Diseases Drugs Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 26 North America Immunology & Inflammatory Diseases Drugs Market Value, 2022-2033 (US$ Billion)
Figure 27 North America Immunology & Inflammatory Diseases Drugs Market Share, By Drug Class, 2024 & 2033 (%)
Figure 28 North America Immunology & Inflammatory Diseases Drugs Market Share, By Disease Indication, 2024 & 2033 (%)
Figure 29 North America Immunology & Inflammatory Diseases Drugs Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 30 North America Immunology & Inflammatory Diseases Drugs Market Share, By Country, 2024 & 2033 (%)
Figure 31 Europe Immunology & Inflammatory Diseases Drugs Market Value, 2022-2033 (US$ Billion)
Figure 32 Europe Immunology & Inflammatory Diseases Drugs Market Share, By Drug Class, 2024 & 2033 (%)
Figure 33 Europe Immunology & Inflammatory Diseases Drugs Market Share, By Disease Indication, 2024 & 2033 (%)
Figure 34 Europe Immunology & Inflammatory Diseases Drugs Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 35 Europe Immunology & Inflammatory Diseases Drugs Market Share, By Country, 2024 & 2033 (%)
Figure 36 Asia-Pacific Immunology & Inflammatory Diseases Drugs Market Value, 2022-2033 (US$ Billion)
Figure 37 Asia-Pacific Immunology & Inflammatory Diseases Drugs Market Share, By Drug Class, 2024 & 2033 (%)
Figure 38 Asia-Pacific Immunology & Inflammatory Diseases Drugs Market Share, By Disease Indication, 2024 & 2033 (%)
Figure 39 Asia-Pacific Immunology & Inflammatory Diseases Drugs Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 40 Asia-Pacific Immunology & Inflammatory Diseases Drugs Market Share, By Country, 2024 & 2033 (%)
Figure 41 South America Immunology & Inflammatory Diseases Drugs Market Value, 2022-2033 (US$ Billion)
Figure 42 South America Immunology & Inflammatory Diseases Drugs Market Share, By Drug Class, 2024 & 2033 (%)
Figure 43 South America Immunology & Inflammatory Diseases Drugs Market Share, By Disease Indication, 2024 & 2033 (%)
Figure 44 South America Immunology & Inflammatory Diseases Drugs Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 45 South America Immunology & Inflammatory Diseases Drugs Market Share, By Country, 2024 & 2033 (%)
Figure 46 Middle East and Africa Immunology & Inflammatory Diseases Drugs Market Value, 2022-2033 (US$ Billion)
Figure 47 Middle East and Africa Immunology & Inflammatory Diseases Drugs Market Share, By Drug Class, 2024 & 2033 (%)
Figure 48 Middle East and Africa Immunology & Inflammatory Diseases Drugs Market Share, By Disease Indication, 2024 & 2033 (%)
Figure 49 Middle East and Africa Immunology & Inflammatory Diseases Drugs Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 50 AbbVie Inc.: Financials
Figure 51 Sanofi: Financials
Figure 52 Regeneron Pharmaceuticals, Inc.: Financials
Figure 53 Johnson & Johnson: Financials
Figure 54 Amgen Inc.: Financials
Figure 55 Novartis Pharmaceuticals Corporation: Financials
Figure 56 Pfizer Inc.: Financials
Figure 57 Merck & Co., Inc.: Financials
Figure 58 Bristol-Myers Squibb Company: Financials
Figure 59 Eli Lilly and Company: Financials
